ValuEngine upgraded shares of TESARO, Inc. (NASDAQ:TSRO) from a sell rating to a hold rating in a research note published on Tuesday, August 1st.
Other equities research analysts have also issued research reports about the company. Janney Montgomery Scott set a $139.00 target price on TESARO and gave the company a hold rating in a research note on Saturday, June 10th. Cowen and Company set a $145.00 target price on TESARO and gave the company a hold rating in a research note on Saturday, June 10th. FBR & Co lowered their target price on TESARO from $200.00 to $195.00 and set a mkt perform rating for the company in a research note on Monday, June 5th. Cann reiterated a buy rating and issued a $199.00 target price on shares of TESARO in a research note on Monday, June 5th. Finally, Robert W. Baird reiterated a neutral rating on shares of TESARO in a research note on Tuesday, June 6th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. TESARO presently has an average rating of Buy and an average target price of $173.47.
TESARO (NASDAQ:TSRO) traded up 4.41% during trading on Tuesday, reaching $113.86. The company’s stock had a trading volume of 1,643,726 shares. TESARO has a 1-year low of $83.26 and a 1-year high of $192.94. The company’s market capitalization is $6.17 billion. The company’s 50-day moving average is $125.98 and its 200-day moving average is $147.86.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by $0.30. The firm had revenue of $29.50 million for the quarter, compared to analyst estimates of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The business’s revenue was down 17.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.28) earnings per share. Equities analysts anticipate that TESARO will post ($8.70) EPS for the current year.
WARNING: This piece was first published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/tesaro-inc-nasdaqtsro-lifted-to-hold-at-valuengine-updated-updated.html.
In other news, VP Edward C. English sold 8,500 shares of TESARO stock in a transaction on Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the transaction, the vice president now directly owns 5,396 shares in the company, valued at approximately $748,155.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 40.50% of the stock is currently owned by company insiders.
Several institutional investors have recently modified their holdings of TSRO. FMR LLC boosted its position in shares of TESARO by 0.4% in the first quarter. FMR LLC now owns 8,043,921 shares of the biopharmaceutical company’s stock valued at $1,237,718,000 after buying an additional 32,918 shares during the period. BlackRock Inc. boosted its position in shares of TESARO by 5.7% in the second quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock valued at $504,230,000 after buying an additional 195,590 shares during the period. Vanguard Group Inc. boosted its position in shares of TESARO by 2.1% in the second quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock worth $416,537,000 after buying an additional 62,104 shares during the last quarter. State Street Corp boosted its position in shares of TESARO by 17.9% in the second quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock worth $163,496,000 after buying an additional 177,057 shares during the last quarter. Finally, BB Biotech AG boosted its position in shares of TESARO by 6.5% in the second quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock worth $122,796,000 after buying an additional 53,408 shares during the last quarter.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.